Dissecting SUMO Activating Enzyme Pathways to Inform Therapy

剖析 SUMO 激活酶途径以指导治疗

• 批准号: MR/X001008/1
• 负责人: Joanna Morris
• 金额: $ 93.14万
• 依托单位: University of Birmingham
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=MR%2FX001008%2F1
• 关键词: Dissecting; SUMO; Activating; Enzyme; Pathways

One cell becomes two by dividing its DNA, in packets of chromosomes, into two daughter cells. This process is supported by a tiny protein that is added to other proteins to help the packets divide correctly. Correct DNA division is particularly important in some cancers that are driven by a particular genetic change, called Myc amplification. New drugs that stop the small protein from being added appear to be useful in killing cancers that have this genetic change. We have recently discovered that the target of those drugs behaves in surprising ways. Instead of having a single role as previously thought, we find it has at least two different functions; one of these is in the poorly understood process of helping DNA remain undamaged as it is divided into the daughter cells. Our aims in this project are to investigate how the drug target behaves in these different ways, to find out which one of them is most important in supporting cancer cell survival, and to discover how it works to prevent DNA damage. This work has implications for how the new drugs are used to help cancer patients.

一个细胞通过将其DNA（将其DNA）划分为两个子细胞，将其DNA分为两个。该过程由一种微小的蛋白质支持，该蛋白被添加到其他蛋白质中，以帮助数据包正确划分。正确的DNA分裂在某些由特定遗传变化驱动的癌症中尤其重要，称为MYC扩增。阻止添加小蛋白的新药物似乎在杀死具有这种遗传变化的癌症中很有用。我们最近发现，这些药物的靶标的表现令人惊讶。我们发现它至少具有两个不同的功能，而不是像以前想到的那样扮演单一角色。其中之一是帮助DNA的理解较少，因为它被分为子细胞，因此仍未受到损坏。我们在该项目中的目标是研究药物靶标的以这些不同方式的行为，以了解其中哪种在支持癌细胞存活中最重要，并发现其如何用于防止DNA损伤。这项工作对如何使用新药来帮助癌症患者有影响。